Amrita Krishnan, MD, of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope in Duarte, California, discussed treatment options for patients with relapsed multiple myeloma presented at the 2019 ASH Annual Meeting, including chimeric antigen receptor (CAR) T-cell therapies. “We have several CAR-T constructs that are being presented, many are B-cell maturation antigen-targeting, but there are some other more novel targets as well, such as dual-targeting CARs and new targets—GPRC5-targeting, for example. I think they’re all very exciting,” she said.
